On November 7, 2019, Tarby, Christine M.; Norris, Derek J.; Lo, Julian C.; Ahuja, Vijay T.; Seitz, Steven P.; Gavai, Ashvinikumar V.; Tokarski, John S.; Rajasagi, Mohini; Wichroski, Michael; Broekema, Matthias published a patent.HPLC of Formula: 64987-16-2 The title of the patent was Preparation of uracil derivatives as Mer-Axl inhibitors. And the patent contained the following:
The invention relates generally to compounds I [Ar1 = aryl or heteroaryl containing 1-4 heteroatoms selected from N, O or S; Ar2 = heteroaryl containing 1-4 heteroatoms selected from N, O or S; Q1 = NHCO, CONH, NHSO2, etc.; Q2 = O or NH; R1 and R2 = (independently) H, (un)substituted alkyl, (CH2)r(cycloalkyl), etc.; R3 and R4 = (independently) H, halo, CF3, etc.; X and Y = (independently) H, halo, alkyl, etc.; r = 0-2] or pharmaceutically acceptable salts, tautomers or stereoisomers thereof, that are Mer-Axl inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. Over one-hundred-forty compounds I were prepared E.g., a multi-step synthesis of II, starting from di-Et 2-(aminomethylene)malonate and 1-fluoro-4-isocyanatobenzene, was described. The inhibitory activity of compounds I was tested in the MERTK, AXL, and TYRO3 activity assays (data given for representative compounds I). The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).HPLC of Formula: 64987-16-2
The Article related to uracil derivative preparation mer axl tyro3 kinase inhibitor antitumor, proliferative disorder dysregulated apoptosis treatment uracil derivative preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 64987-16-2
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica